| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dac022280ec96f54c694eb427655932
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38090aefd75e16e476821c235e2f0409 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-556 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-403
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2002-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b1076207364484eb71b861034e8427f7 |
| publicationDate |
2003-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03032963-A2 |
| titleOfInvention |
Method of reducing type 2 diabetes in high risk patients |
| abstract |
The present invention relates to the use of an angiotensin converting enzyme (ACE) inhibitor such as ramipril or a pharmaceutically acceptable derivative thereof in the manufacture of a medicament for the prevention or reduction of the onset of diabetes in patients who are at risk for developing diabetes; for the prevention, slowing or reversing the decline of beta-cell function; for increasing islet blood flow; for increasing pancreatic beta-cell perfusion; and for lowering aldosterone secretion and renal potassium wasting. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004080482-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004080482-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005020984-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2005020984-A3 |
| priorityDate |
2001-10-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |